Bill Doyle of Novocure, a company that developed non-invasive technology to control cell division in glioblastoma tumors, spoke at TEDMED 2012 about the role low-intensity alternating electric fields can have on cancer therapy:


This post also appears on medGadget, an Atlantic partner site.

We want to hear what you think about this article. Submit a letter to the editor or write to letters@theatlantic.com.